Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

被引：34

作者：

Kosmider, Olivier ^{[1
]}

Passet, Marie ^{[1
]}

Santini, Valeria ^{[2
]}

Platzbecker, Uwe ^{[3
]}

Andrieu, Valerie ^{[4
]}

Zini, Gina ^{[5
]}

Beyne-Rauzy, Odile ^{[6
]}

Guerci, Agnes ^{[7
]}

Masala, Erico ^{[8
]}

Balleari, Enrico ^{[9
]}

Bulycheva, Ekaterina ^{[3
]}

Dreyfus, Francois ^{[10
]}

Fenaux, Pierre ^{[11
]}

Fontenay, Michaela ^{[1
]}

Park, Sophie ^{[12
]}

机构：

[1] Hop Cochin, AP HP, Hematol Biol, Paris, France

[2] Univ Florence, AOU Careggi, Hematol, I-50121 Florence, Italy

[3] Univ Hosp Carl Gustav Dresden, Dresden, Germany

[4] Hop Bichat Claude Bernard, AP HP, Hematol Biol, Paris, France

[5] Univ Cattolica Sacro Cuore, Rome, Italy

[6] Oncopole, IUCT, Toulouse, France

[7] Hop Brabois, Nancy, France

[8] Univ Florence, Florence, Italy

[9] IRCCS AOU San Martino IST Genova, Genoa, Italy

[10] Hop Cochin, Serv Hematol, Paris, France

[11] Hop St Louis, Serv Hematol Seniors, Paris, France

[12] Univ Grenoble Alpes, CHU Grenoble Alpes, Clin Univ Hematol, Grenoble, France

来源：

HAEMATOLOGICA | 2016年 / 101卷 / 07期

关键词：

myelodysplastic syndromes; cytogenetics and molecular genetics; red cells; SURVIVAL; IMPACT; MODEL;

D O I：

10.3324/haematol.2016.142695

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：280 / 283

页数：4

共 50 条

[21] Management of Lower-Risk Myelodysplastic Syndromes: The Art and Evidence [J].

Komrokji, Rami S. ;

Sekeres, Mikkael A. ;

List, Alan F. .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (02) :145-153

[22] Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes [J].

Musto, Pellegrino ;

Maurillo, Luca ;

Spagnoli, Alessandra ;

Gozzini, Antonella ;

Rivellini, Flavia ;

Lunghi, Monia ;

Villani, Oreste ;

Aloe-Spiriti, Maria Antonietta ;

Venditti, Adriano ;

Santini, Valeria .

CANCER, 2010, 116 (06) :1485-1494

[23] Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents [J].

Kelaidi, C. ;

Park, S. ;

Sapena, R. ;

Beyne-Rauzy, O. ;

Coiteux, V. ;

Vey, N. ;

Stamatoullas, A. ;

Choufi, B. ;

Delaunay, J. ;

Gourin, M-P ;

Cheze, S. ;

Ravoet, C. ;

Ferrant, A. ;

Escoffre-Barbe, M. ;

Aljassem, L. ;

Raffoux, E. ;

Itzykson, R. ;

Ades, L. ;

Dreyfus, F. ;

Fenaux, P. .

LEUKEMIA, 2013, 27 (06) :1283-1290

[24] Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study [J].

Ball, Brian J. ;

Song, Rui ;

Zanardo, Enrico ;

Huynh, Lynn ;

Mohan, Manasi ;

Pinaire, Megan ;

Tang, Derek ;

Yenikomshian, Mihran ;

Swanson, Ashley ;

Gavrilov, Svetlana ;

Slaff, Samantha .

JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) :719-725

[25] Variations in erythropoiesis-stimulating agent administration intransfusion-dependent myelodysplastic syndromes impact response [J].

Duong, Vu H. ;

Baer, Maria R. ;

Hendrick, Franklin ;

Weiss, Sheila R. ;

Sato, Masayo ;

Zeidan, Amer M. ;

Gore, Steven D. ;

Davidoff, Amy J. .

LEUKEMIA RESEARCH, 2015, 39 (06) :586-591

[26] Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome [J].

Garelius, H. K. G. ;

Johnston, W. T. ;

Smith, A. G. ;

Park, S. ;

de Swart, L. ;

Fenaux, P. ;

Symeonidis, A. ;

Sanz, G. ;

Cermak, J. ;

Stauder, R. ;

Malcovati, L. ;

Mittelman, M. ;

van de Loosdrecht, A. A. ;

van Marrewijk, C. J. ;

Bowen, D. ;

Crouch, S. ;

de Witte, T. J. M. ;

Hellstrom-Lindberg, E. .

JOURNAL OF INTERNAL MEDICINE, 2017, 281 (03) :284-299

[27] Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents [J].

Park, Sophie ;

Hamel, Jean-Francois ;

Toma, Andrea ;

Kelaidi, Charikleia ;

Thepot, Sylvain ;

Diez Campelo, Maria ;

Santini, Valeria ;

Sekeres, Mikkael A. ;

Komrokji, Rami ;

Steensma, David ;

Balleari, Enrico ;

Goetze, Katharina S. ;

Kotsianidis, Ioannis ;

Guerci-Bresler, Agnes ;

Stamatoullas, Aspasia ;

Sanz, Guillermo F. ;

Germing, Ulrich ;

Fenaux, Pierre .

LEUKEMIA RESEARCH, 2020, 99

[28] Treatment of Lower Risk Myelodysplastic Syndromes [J].

Santini, Valeria .

HEMATO, 2022, 3 (01) :153-162

[29] APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis [J].

Raimbault, Anna ;

Pierre-Eugene, Cecile ;

Rouquette, Alexandra ;

Deudon, Celine ;

Willems, Lise ;

Chapuis, Nicolas ;

Mathis, Stephanie ;

Kunz, Claudia ;

Fricke, Harald ;

Kosmider, Olivier ;

Bardet, Valerie ;

Fontenay, Michaela .

ONCOTARGET, 2016, 7 (12) :14898-14911

[30] A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents [J].

Thepot, Sylvain ;

Ben Abdelali, Raouf ;

Chevret, Sylvie ;

Renneville, Aline ;

Beyne-Rauzy, Odile ;

Prebet, Thomas ;

Park, Sophie ;

Stamatoullas, Aspasia ;

Guerci-Bresler, Agnes ;

Cheze, Stephane ;

Tertian, Gerard ;

Choufi, Bachra ;

Legros, Laurence ;

Bastie, Jean Noel ;

Delaunay, Jacques ;

Chaury, Marie Pierre ;

Sanhes, Laurence ;

Wattel, Eric ;

Dreyfus, Francois ;

Vey, Norbert ;

Chermat, Fatiha ;

Preudhomme, Claude ;

Fenaux, Pierre ;

Gardin, Claude .

HAEMATOLOGICA, 2016, 101 (08) :918-925

← 1 2 3 4 5 →